Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.

Slides:

Advertisements

Similar presentations

Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de.

Advertisements

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma by René-Olivier Casasnovas,

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,

Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis by Katharine H.

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.

A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma by Anamarija M. Perry, Teresa.

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.

EBV-positive diffuse large B-cell lymphoma of the elderly by Chi Young Ok, Thomas G. Papathomas, L. Jeffrey Medeiros, and Ken H. Young Blood Volume 122(3):

A Randomized Phase 3 Study of Peripheral Blood Progenitor Cell Mobilization With Stem Cell Factor and Filgrastim in High-Risk Breast Cancer Patients by.

Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.

TCR-MHC-peptide(s): in vivo veritas

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative.

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

by James O. Armitage, and Dan L. Longo

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Tax fingerprint in adult T-cell leukemia

Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)‏ by Nicolas.

by Thomas Rasmussen, Linda Jensen, Lone Honoré, and Hans Erik Johnsen

Nonmyeloablative conditioning for relapsed follicular lymphoma

Superior Survival after Autologous vs

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,

Protease inhibitors potentiate chemotherapy-induced neutropenia

A Novel Method of Amplification of FFPET-Derived RNA Enables Accurate Disease Classification with Microarrays P. Mickey Williams, Rui Li, Nathalie A.

by Fangxin Hong, Thomas M Habermann, Leo I

Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Stage C or not stage C…? by Claire Dearden Blood

Primary testicular lymphoma

CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.

Lymphoma spread? Target CD47-SIRPα!

How I treat refractory CLL

TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma by David W. Scott, Karen L. Mungall, Susana Ben-Neriah, Sanja Rogic, Ryan D.

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue by David W. Scott,

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy by Vindi Jurinovic, Robert Kridel, Annette.

Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL by Monika Pilichowska, Stefania Pittaluga,

Superiority of Obinutuzumab over Rituximab in a New Molecular Follicular Lymphoma-like Subgroup of DLBCL: Results from an Exploratory Analysis of the Phase.

High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology by Lauren C. Chong, Susana Ben-Neriah, Graham W.

PD-L1 and tumor-associated macrophages in de novo DLBCL

sIgM levels or signaling and FISH lesions in CLL

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

FCM and TCR γ gene rearrangement analysis in LGL leukemia.

Anti-CD20-IL-21 fusokine: the tail wags the dog

Biology and treatment of Richter syndrome

by Pierre Sesques, and Nathalie A. Johnson

Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma.

Relationship of PMBL to Hodgkin lymphoma.

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

How I treat early-relapsing follicular lymphoma

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk.

Full Uncapped Doses Of Chemotherapy In Non-Hodgkin's Lymphoma Patients With a High Body Surface Area Are Well Tolerated With No Increase In Toxicity, and.

Patient Tregs express normal levels of suppression.

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

Cold agglutinin disease

Presentation transcript:

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen Leach, Angela Brooks-Wilson, Laurie H. Sehn, Mukesh Chhanabhai, Ryan R. Brinkman, Joseph M. Connors, Andrew P. Weng, and Randy D. Gascoyne Blood Volume 113(16): April 16, 2009 ©2009 by American Society of Hematology

CD20 and CD19 expression in DLBCL by flow cytometry. Nathalie A. Johnson et al. Blood 2009;113: ©2009 by American Society of Hematology

CD20 expression by IHC and FCM of representative “dim” CD20 and “bright” CD20 DLBCL samples. Nathalie A. Johnson et al. Blood 2009;113: ©2009 by American Society of Hematology

Overall survival. Nathalie A. Johnson et al. Blood 2009;113: ©2009 by American Society of Hematology

Overall survival of patients with DLBCL according to CD5 expression. Nathalie A. Johnson et al. Blood 2009;113: ©2009 by American Society of Hematology